Serum Free Light Chains (Free light chains)
The haematological neoplasms that arise through primarily tumours of the B-cell haematopoietic lineage and subsequent plasma cells comprise a wide range of disorders that include the multiple myelomas, Waldenström’s macroglobulinaemia, AL amyloidosis (primary systemic amyloidosis), heavy chain disease and the plasmacytomas. Disease is typically characterised by secretion of monoclonal immunoglobulins, their free light chain components or fragments thereof, and diagnosis and staging of disease progression often employs the systematic assay of these specific proteins over time.
NWLP Serum Electrophoresis Interpretation Local Guidance (2023)
NWLP GP Electrophoresis and Free Light Chain Quick Guide Mar (2023)
Serum FLC assay is of greater clinical utility than urinary BJP assay in diagnosis of non-Ig secretory multiple myeloma. Stratification of risk for development of multiple myeloma in MGUS cohorts. Staging of established malignancy Assessment of response to chemotherapeutic intervention (especially with regard to AL amyloidosis, light chain and non-secretory multiple myeloma). Prognostic indicator/tumour marker for detection of residual tumour or cancer recurrence.
It is recommended that serum protein electrophoresis and serum free light chains (sFLC) are used to determine the presence of a paraprotein, which may indicate possible myeloma or monoclonal gammopathy of undetermined significance (NG35). Approximately 20% of cases of myeloma do not have a detectable intact immunoglobulin: do not use serum protein electrophoresis, sFLC or BJP alone to exclude a diagnosis of myeloma.
BJP analysis may prove useful where there are marginally increases/decreases in the serum free light chain ratio.
Free Kappa chains: 3.3-19.4 mg/L Free Lambda chains: 5.7-26.3 mg/L
Kappa:Lambda ratio:0.26-1.65
For impaired renal function: sFLC Ratio reference range is 0.37 to 3.10
Grossly haemolysed samples are unsuitable for this assay.
Serum Free Light Chain Local Guidance:
- sFLC ratio ≤0.01 or ≥100: Myeloma related event (MRE), requiring urgent referral
- Abnormal sFLC ratio in MGUS indicates higher progression risk
- sFLC ratio ≤0.125 or ≥8 in smouldering/asymptomatic myeloma: increased progression risk
| sFLC Ratio | Action |
| ≥100 or ≤0.01 | Meets criteria for symptomatic myeloma
Urgent referral to Haematology |
| >10 or <0.1 | Abnormal serum free light chain ratio. Suggest referral and/or discussion with Haematology |
| 0.1 – 0.2
or 5 – 10 |
Mildly abnormal serum free light chain ratio. ?Possible Light Chain only MGUS, amyloidosis or other light chain disorder. Suggest discuss with Haematology |
| 0.2 – 0.25
or 1.66 – 5 |
Likely minor abnormality of sFLC. If normal serum electrophoresis, likely causes may include inflammation or impaired renal function. Consider measurement of urine Bence Jones protein |
| For impaired renal function: sFLC Ratio reference range is 0.37 to 3.10 | |
Record last updated
September 18, 2025
Sample Container
5ml SST Vacutainers (Gold / Yellow top)
Sample Container
6ml Plain Vacutainers (Red top)
Search test database
Test Results
Yes, we have a Pathology User Guide
Yes. Please email your request to Imperial.nwlpcustomerservice@nhs.net
Results are communicated to clinical staff and are normally not communicated direct to patients either on telephone requests or in written report. If you need to contact us please click here to view the contact details page
Please contact the Customer Service Team Monday to Friday from 8:30am – 6:00pm on 0203 313 5353. Alternatively, see the Pathology User Guide for how to contact the relevant department. If advice is not urgent you can also email your query to Imperial.nwlpcustomerservice@nhs.net
Additional tests may be added by discussion with the relevant laboratory. The time limit for adding additional tests to a sample already received in the laboratory will depend on the type of sample and the department it was sent to.
Information on the repertoire of tests performed by pathology, including reference ranges, turnaround times and specimen requirements, can be found in the test directory.
Phlebotomy services are not managed by NWLP. For further information please see:
Imperial College Healthcare Trust Phlebotomy services
Chelsea and Westminster Hospital NHS Foundation Trust Phlebotomy services
NWLP operates UKAS accredited medical laboratories as per the references below. The current scope of accreditation for all NWLP’s laboratories can be found on the UKAS website.
See the following UKAS ref numbers:
- Clinical Biochemistry Ref: 8673
- Haematology and Blood Transfusion Ref: 8674
- Infection & Immunity Sciences (Including Immunology, Virology, Microbiology and Histocompatibility and Immunogenetics ) Ref: 8659
- Cellular Pathology (Including Histopathology, Cytology and Molecular Pathology) Ref: 9615
If you require copies of our certificate of accreditation and associated documentation please contact Imperial.nwlpcustomerservice@nhs.net.
UKAS requires the laboratories to be accredited for a particular repertoire/scope (ISO15189), any changes or additions to repertoire require assessment by UKAS (extension to scope).
The BD Hospital Tube Guide, BD GP Tube Guide and BD Paediatric Tube Guide provide visual references to the correct tube types and collection instructions.
Home testing
INSTRUCTION SHEET FOR BLOOD SAMPLE COLLECTION
We also have two instruction videos available (one with subtitles and one without) – please click on the links to view the videos on Google.
Our accreditations
Upholding excellence in diagnostic standards
Our laboratories are accredited by the UK Accreditation Service (UKAS) against the international standard ISO15189:2022. UKAS is the accreditation body for the UK that assesses medical laboratories.
Find out more about our accreditations on the UKAS website.
UKAS website